tirzepatide surmount-1 nejm 2022 weight loss percent vs. Semaglutide for Patients with Obesity: A Head-to-Head Trial https://jwat.ch/3ZijGUc Tirzepatide: In the SURMOUNT-1 trial,

83 TournierN.DeclevesX.SaubameaB.ScherrmannJ.-M.CisterninoS

If you forget to inject yourself with semaglutide, contact our primary care provider immediately and discuss further relevant measures concerning missed dose immediately

Science and community fully agree on core findings: tirzepatide produces 20%+ weight loss at maximum tolerated doses, GI side effects are the limiting factor during titration, and weight returns when stopped

When your labs and history line up, medical weight loss addresses the cause instead of just lowering the number on the scale

This distinction helps explain why many patients feel they've 'failed' when rebound occurs

(Study: Frias et al., 2021) Mounjaro Mounjaro, also known as sotagliflozin, belongs to the class of sodium-glucose cotransporter-1 and -2 (SGLT-1/2) inhibitors